1. Citrobacter youngae nosocomial bacteremia from postoperative pyogenic spondylodiscitis after a minimally invasive spinal surgery.
- Author
-
Thau NS, Van Dong D, Nhan PTT, Van Tuan N, and Sang VV
- Subjects
- Humans, Male, Aged, Cross Infection microbiology, Minimally Invasive Surgical Procedures, Postoperative Complications microbiology, Postoperative Complications drug therapy, Magnetic Resonance Imaging, Discitis microbiology, Discitis drug therapy, Bacteremia microbiology, Bacteremia drug therapy, Anti-Bacterial Agents therapeutic use, Enterobacteriaceae Infections microbiology, Enterobacteriaceae Infections diagnosis, Enterobacteriaceae Infections drug therapy, Citrobacter isolation & purification
- Abstract
Citrobacter youngae (C. youngae) was first described in 1993, and data suggesting that human diseases caused by this bacterium remain scarce. Reports on C. youngae infections mostly described local infections without evidenced bacteremia, especially in immunocompromised patients. Herein, we report a rare case of bacteremia with intervertebral disc and adjacent vertebral infection due to C. youngae (detected by the Vitek
® 2 Compact). A 70-year-old man with chronic lower back pain due to lumbar disc herniation underwent microdiscectomy, a minimally invasive spinal surgery. On postoperative day 4, he suffered shaking chills with worsened lower back pain compared to that before the operation, and vancomycin plus ceftriaxone were empirically administered. Magnetic resonance imaging (MRI) of the lumbar spine revealed osteomyelitis at L4 and L5 with L4/L5 discitis. Two blood culture sets were positive with the same pathogen, possibly C. youngae; The patient was then treated successfully with ceftazidime plus ciprofloxacin, the antibiotics were selected based on antibiotic susceptibility test results. This report suggests that C. youngae may cause severe infections in immunocompetent patients, and further surveillance should be considered to monitor antibiotic-resistant bacteria., Competing Interests: Declarations. Ethical approval and consent to participate: The patient has agreed to participate in this case report by giving informed consent. Consent for publication: The patient agreed to publish his clinical and subclinical details by providing a signed informed consent document. Competing interests: The authors declare no competing interests., (© 2024. The Author(s).) more...- Published
- 2024
- Full Text
- View/download PDF